

Supplementary Figures

Figure S1




Figure S1. Starvation effects on medaka larvae.

(A) The survival rate during starvation treatment from 0–6 dph (0 dph $n = 145$, 1 dph fed $n = 130$, 1 dph starved $n = 143$, 2 dph fed $n = 141$, 2 dph starved $n = 128$, 3 dph fed $n = 144$, 3 dph starved $n = 134$, 4 dph fed $n = 147$, 4 dph starved $n = 137$, 5 dph fed $n = 135$, 5 dph starved $n = 130$, 6 dph fed $n = 144$, 6 dph starved $n = 144$). dph, day post hatching. The values indicate the average and the bars indicate s.e.m..

(B) Body length during starvation treatment from 0–6 dph. A significant difference appears at 3 dph (0 dph $n = 45$, 1 dph fed $n = 30$, 1 dph starved $n = 43$, 2 dph fed $n = 41$, 2 dph starved $n = 28$, 3 dph fed $n = 44$, 3 dph starved $n = 34$, 4 dph fed $n = 47$, 4 dph starved $n = 37$, 5 dph fed $n = 35$, 5 dph starved $n = 30$). The values indicate the average and the bars indicate s.e.m.. Student's t-test was used as statistical analysis. * P -value < 0.05 .

(C) The presence of the yolk ball during starvation treatment from 0–5 dph. The yolk ball disappears until 2 dph under normal feeding conditions (0 dph $n = 148$, 1 dph fed $n = 150$, 1 dph starved $n = 150$, 2 dph fed $n = 151$, 2 dph starved $n = 145$, 3 dph fed $n = 151$, 3 dph starved $n = 149$, 4 dph fed $n = 151$, 4 dph starved $n = 147$, 5 dph fed $n = 146$, 5 dph starved $n = 150$). The values indicate the average.

(D) The appearance of dorsal and anal fins and gonads in the medaka d-rR strain. Sex-reversed individual indicates a male type of dorsal and anal fins with normal testis. The genotyping result is shown in Table 1. Scale bars: 1 mm.

(E) Principal component analysis based on metabolomic analysis (IC-FTMS and LC-MS/MS, 250 metabolites). Both XX and XY show different metabolic profiles depending on feeding conditions (fed XX $n = 5$, fed XY $n = 4$, starved XX $n = 5$, starved XY $n = 5$). Principal component, PC

(F) Loading plot of principal component analysis. A point indicates metabolite. Pantothenate shows a high contribution to the positive side of principal component 1. Principal component, PC

Figure S2




Figure S2. Analysis of medaka *pank* genes.

(A) Synteny analysis for *pank1* gene. *pank1b* is not found in the syntenic region in the medaka LG19.

(B) Synteny analysis for *pank3* gene. *pank3* is not found in the syntenic region in the medaka LG10.

(C-F) *pank1a* expression was examined by whole mount *in situ* hybridization at 5 dph. Strong signals are detected in the gut and liver of both sexes (C, D). *pank1a* transcripts are not detected in the gonad (E, F). Black dashed lines indicate the outlines of the gonads. White arrowheads indicate germ cells with negative signals. g, gut; l, liver; n, nephric duct. Scale bars: 40 μm (C, D), 10 μm (E, F).

Figure S3




Figure S3. Pank inhibitor treatment does not affect larval growth but causes pantothenate accumulation.

(A) The amount of pantothenate after 5 days of Pank inhibitor treatment. XX larvae treated with Pank inhibitor indicate the increase of pantothenate (XX DMSO $n = 8$, XX inhibitor $n = 8$, XY DMSO $n = 8$, XY inhibitor $n = 8$). The vertical axis indicates the peak area of pantothenate in the spectrogram of IC-FTMS analysis. The values indicate the average and the bars indicate s.e.m.. A two-way ANOVA followed by Dunnett test was used as statistical analysis. *: P -value < 0.05 in Dunnett test.

(B) Body length at 5 dph under Pank inhibitor (50 μ M) treatment. Treated larvae show normal body length (XX DMSO $n = 24$, XX inhibitor $n = 26$, XY DMSO $n = 15$, XY inhibitor $n = 21$). The values indicate the average and the bars indicate s.e.m.. A two-way ANOVA followed by Dunnett test was used as statistical analysis.

(C) Body weight after 5 days of Pank inhibitor treatment. The weight of a single larva was calculated from the results of measurement using 4-6 larvae. (DMSO = 8 times, inhibitor = 9 times). Larvae treated with Pank inhibitor show normal body weight. The values indicate the average and the bars indicate s.e.m.. Student's t -test was used as statistical analysis.

(D) Principal component analysis based on metabolomic analysis (IC-FTMS, 141 metabolites). Pank inhibitor (PI, 50 μ M)-treated larvae show a starved-like metabolic profile (fed XX $n = 4$, fed XY $n = 5$, starved XX $n = 5$, starved XY $n = 5$, PI XX $n = 5$, PI XY $n = 5$). One dot indicates a data set of a single larva.

(E) Loading plot of principal component analysis. A point indicates metabolite. Pantothenate shows a high contribution to the positive side of principal component 1. Principal component, PC

Figure S4




Figure S4. The effects of C75 (FAS inhibitor) treatment.

(A) Synteny analysis for *fasn* gene on medaka genome. The paralogue for *fasn* is not found on the medaka LG8.

(B) Body length at 5 dph under C75 treatment (20 $\mu\text{g}/\text{mL}$). Treated larvae show normal body length (DMSO $n = 19$, C75 $n = 17$). The values indicate the average and the bars indicate s.e.m.. Student's t-test was used as statistical analysis.

(C) Principal component analysis based on metabolic analysis (ICFTMS, LC-MS/MS, 250 metabolites). C75 (20 $\mu\text{g}/\text{mL}$)-treated larvae do not show a starved-like metabolic profile (fed XX $n = 5$, fed XY $n = 4$, starved XX $n = 5$, starved XY $n = 5$, C75 XX $n = 3$, C75 XY $n = 5$).

(D) Loading plot of principal component analysis. A point indicates metabolite. Pantothenate shows a high contribution to the positive side of principal component 1. Principal component, PC

(E) Gonad from C75-treated fish (most right). Sex-reversed individuals have normal testis. Scale bars: 1 mm.

Figure S5




Figure S5. *fasn* disruption by CRISPR/Cas9 system.

(A) Design of gRNAs for disruption of *fasn* gene. The two different gRNAs were designed based on exon 4 of the *fasn* gene.

(B) The body appearance of G0 adult medaka. The G0 adult medaka show a short body length with a swollen belly.

Figure S6




Figure S6. Design of TALEN for *dmrt1* disruption.

(A) The location of left and right TALEN arms on the *dmrt1* gene. TALEN was designed based on exon 1 of the *dmrt1* gene.

(B) The sequence of *dmrt1* in Δ13 line.

(C) The expected amino acid sequence of *dmrt1* in Δ13 line. *: stop codon.

Table S1. Primers and TaqMan probes used in this study.

Experiment	primer name	sequence (5'-3')
genotyping	tq-dmy-F	CGGTAAAATTGACGCACAGCAT
	tq-dmy-R	GGTGATTACTTGTGTTTCCACATTT
	dmy-FAM (TaqMan probe)	TGGCTTACCGTTGGA
	tq-cyp19a-F	TGGCACAGCCAGCAACTATTA
	tq-cyp19a-R	TCCGTTGATCCACACTCGAA
	cyp19a-VIC (TaqMan probe)	ACAACAAATATGGAGACTT
	dmrt1-typing-F1	TCCTGTACAAGTGACCCCGC
	dmrt1-typing-R1	TTCAGCGGAGACACGAAGCC
In situ hybridization	fasn probe F	TGGAGATCGGGAAGTACGAC
	fasn probe R	GGCCAGTGAATTGTAATACGACTCACTATAGGGAAGTGGTCCAACACCTCCAG
	pank1a probe F	CGTCCACTTGGAGCTGAGAA
	pank1a probe R	GGCCAGTGAATTGTAATACGACTCACTATAGGGTCACGAGTCATCTGTTGTC
fasn KO	fasn gRNA1 F	TAATACGACTCACTATAGGCCTCCAGCCTGCTGGCGT
	fasn gRNA1 R	TTCTAGCTCTAAAACACGCCAGCAGGCTGGAGG
	fasn gRNA2 F	TAATACGACTCACTATAGGACGCTGCTCTGGTGGGTG
	fasn gRNA2 R	TTCTAGCTCTAAAACACCCACCAGAGCAGCGT
	80nt-crRNA-F	GTTTTAGAGCTAGAAATAGCAAGTTAAATAAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCCAGTCCGGTCTTTT
	80nt-crRNA-R	AAAAGCACCGACTCGGTGCCATTTTTCAAGTTGATAACGGACTAGCCTATTTTAACTTGCTATTCTAGCTCTAAAAC
	T7-F	TAATACGACTCACTATAG
	crRNA-R	AAAAGCACCGACTCGGTG
	fasn check F	CCAGAGGAACGGTTGTTTTTC
	fasn check R	TGAGCATGCCCAAGTTTCAT
RT-qPCR	b-actin F	TGGCGCTTGACTCAGGATTT
	b-actin R	GCAGATGCCTGGGGTGTTTA
	cyp19a1a F	CGCACAGAGTTCTTCCACAAAAG
	cyp19a1a R	AACGGCTGAAAATAACGACGA
	foxl2 F	CACGCTGTCTGGCATCTACC
	foxl2 R	TCGTTGAGGCTCAGGTTGTG
	dmrt1 F	AGGGCCCGGCTCCGGCTCCA
	dmrt1 R	TTCAGCGGAGACACGAAGCC
	gsdf F	TCCATGGCCACCGAGGTCTT
	gsdf R	CCGAGGAATTGCAGAGAGCAC
	pank1a F	GCTTTGGAAATGGCCAGTAA
	pank1a R	CATGTGACCAAAGCTGGATG
	pank2 F	CACCCTCTCCATGAAGCTGT
	pank2 R	GATGCAGCAACTCAAGCAAG
	pank4 F	TCACCGTCAGGAGTCTGTTG
	pank4 R	TCGTTCTCCCTCTGCTTGAT